Pegfilgrastim

Generic Name
Pegfilgrastim
Brand Names
Fulphila, Fylnetra, Neulasta, Udenyca, Ziextenzo, Cegfila (previously Pegfilgrastim Mundipharma), Nyvepria, Pelgraz, Grasustek, Pelmeg, Stimufend
Drug Type
Biotech
Chemical Formula
-
CAS Number
208265-92-3
Unique Ingredient Identifier
3A58010674
Background

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of de...

Indication

Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non­ myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
...

Associated Conditions
Chemotherapy Induced Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Infection
Associated Therapies
-
Clinical Trials
Related News

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

First Posted Date
2024-12-17
Last Posted Date
2024-12-17
Lead Sponsor
University of Washington
Target Recruit Count
30
Registration Number
NCT06738368
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination with Vincristine and Temozolomide in Adolescents and Young Adults with Relapsed or Refractory Sarcomas

First Posted Date
2024-11-28
Last Posted Date
2024-11-28
Lead Sponsor
David S Shulman, MD
Target Recruit Count
63
Registration Number
NCT06709495
Locations
🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

First Posted Date
2024-07-30
Last Posted Date
2024-12-16
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
52
Registration Number
NCT06528691
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

First Posted Date
2024-07-25
Last Posted Date
2024-07-25
Lead Sponsor
The Affiliated People's Hospital of Ningbo University
Target Recruit Count
99
Registration Number
NCT06520176
Locations
🇨🇳

Dongyang People's Hospital, Dongyang, Zhejiang, China

🇨🇳

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

🇨🇳

The First Hospital of Jiaxing, Jiaxing, Zhejiang, China

and more 13 locations

GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)

First Posted Date
2024-03-13
Last Posted Date
2024-03-13
Lead Sponsor
Queen Mary University of London
Target Recruit Count
36
Registration Number
NCT06309732
Locations
🇬🇧

Barts and the London NHS Trust, London, United Kingdom

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

First Posted Date
2024-01-23
Last Posted Date
2024-08-19
Lead Sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Target Recruit Count
324
Registration Number
NCT06220032
Locations
🇳🇱

NL-Breda-AMPHIA, Breda, Netherlands

🇳🇱

NL-Almelo-ZGTALMELO, Almelo, Netherlands

🇳🇱

NL-Amstelveen-AMSTELLAND, Amstelveen, Netherlands

and more 22 locations

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

First Posted Date
2024-01-03
Last Posted Date
2024-01-03
Lead Sponsor
National Research Center for Hematology, Russia
Target Recruit Count
100
Registration Number
NCT06188676
Locations
🇷🇺

National Research Center for Hematology, Moscow, Russian Federation

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

First Posted Date
2023-05-23
Last Posted Date
2024-08-29
Lead Sponsor
Sutro Biopharma, Inc.
Target Recruit Count
600
Registration Number
NCT05870748
Locations
🇺🇸

Texas Oncology, Dallas, Texas, United States

🇺🇸

Ohio State University Center, Columbus, Ohio, United States

🇺🇸

Baptist Health South Florida (BHSF) - Miami Cancer Institute, Miami, Florida, United States

and more 36 locations

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

First Posted Date
2022-12-09
Last Posted Date
2024-07-19
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
27
Registration Number
NCT05645718
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Comparison of Quality and Quantity of M-PRP Cellular Content Filgrastim vs. Pegfilgrastim

Recruiting
Conditions
Healthy
Interventions
Drug: Filgrastim
Drug: Pegfilgrastim
First Posted Date
2022-10-10
Last Posted Date
2022-10-10
Lead Sponsor
Andrews Research & Education Foundation
Target Recruit Count
10
Registration Number
NCT05573386
Locations
🇺🇸

Andrews Research and Education Foundation, Gulf Breeze, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy